Brookline Capital Management issued their Q3 2025 earnings estimates for shares of CRISPR Therapeutics in a report released ...

We recently published a list of Shares of 10 Firms Soar on Friday. In this article, we are going to take a look at where ...

CRISPR's upcoming trial data and increasing demand for Casgevy drive Evercore's bullish outlook and a higher price target ...

Evercore ISI has upgraded CRISPR (CRSP) to outperform from in line, citing upcoming data catalysts. Read more here.

Evercore ISI analyst Liisa Bayko raised the price target for CRISPR Therapeutics from $60.00 to $99.00. Bayko's optimism is driven by upcoming catalysts that could mark a new chapter for the company.

Insperity Inc is a company that provides a wide range of human resources and business solutions designed to help businesses improve their performance. Small and midsize enterprises are the company's ...

Fintel reports that on February 14, 2025, Evercore ISI Group upgraded their outlook for CRISPR Therapeutics (NasdaqGM:CRSP) ...

In a report released today, Terence Flynn from Morgan Stanley maintained a Sell rating on Crispr Therapeutics AG (CRSP – Research Report), with ...

Healthcare isn't the hottest sector these days. While the S&P 500 has soared nearly 21% over the last 12 months, healthcare ...

CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) had its price target hoisted by Barclays from $55.00 to $56.00 in a note ...